TearLab has announced plans to strengthen its position in corneal health under the new name Trukera Medical. The company's renaming reflects its goals and long-term expansion plans, which include addressing a wider range of unmet requirements in corneal health.
“We continue to remain dedicated to the advancement of corneal health. Our decision to rebrand as Trukera Medical represents our history as pioneers of point-of-care testing for corneal disease, while also more clearly reflecting where we’re going next,” Trukera Medical CEO Adam Szaronos said in a company news release.
Adam Szaronos added that they expect to see continued growth ahead with point-of-care diagnostics, driven primarily by practices specializing in cornea and premium cataract/refractive surgery.
TearLab Osmolarity System
In 2010, TearLab launched the TearLab Osmolarity System, introducing osmolarity testing as an objective diagnostic tool for the eye care industry. Over 24 million tests with the gadget have been done globally since then.
The ASCRS OSD Algorithm deemed osmolarity an “essential” preoperative diagnostic test for cataract and refractive surgeries. It will remain a flagship device in the Trukera Medical portfolio.
“Corneal health is an exciting focus for us because precise, predictive and practical corneal evaluation can inform treatment in all aspects of ocular health,” said James V. Mazzo, Executive Chairman of the Board at Trukera Medical. “Customers have expanded the use of osmolarity testing from aiding in the diagnosis and management of corneal disease to ensuring risk factors are identified for minimizing refractive surprises after surgery. As Trukera, we’re looking forward to helping improve patients’ lives even further by advancing doctors’ capabilities around corneal health.”
Later this month, Trukera Medical will make the first announcement regarding its newest product, which will be unveiled at the next World Cornea Congress and American Academy of Ophthalmology conferences.
1. Starr CE, Gupta PK, Farid M, et al. An algorithm for the preoperative diagnosis and treatment of ocular surface disorders. J Cataract Refract Surg. 2019 May;45(5):669-684. doi: 10.1016/j.jcrs.2019.03.023.